A trial to see if it is possible to regenerate brains in patients that have been declared clinically dead has been approved. Reanima Advanced Biosciences aims at using stem cells, injections of peptides, and nerve stimulation to cause regeneration in brain dead patients. The primary outcome measure is “reversal of brain death as noted in clinical examination or EEG”, which at least scores high on ambition. The study accepts healthy volunteers, but they need to be brain dead due to traumatic brain injury, which might discourage most people.
Is there any problem with this? Continue reading
Nearly everyone would agree that a device or drug that relieves pain, or alleviates symptoms of depression confers a benefit – plausibly, a substantial benefit – on its user. No matter what your goals are, no matter what you enjoy, you are likely to agree that your life will go better if you are not in pain and not depressed: whether you’re a painter, a footballer, a Sudoku-enthusiast or a musician, you will be better able to pursue your projects and engage in the activities you love. It is unlikely that you will even question whether pain relief or alleviation of depression indeed constitute benefits.
This general consensus with respect to medical benefits makes it relatively straightforward for regulators to conduct risk-benefit assessments of medical products when they decide whether a particular product can be put on the market. A very small risk of a mild rash or gastrointestinal upset, for example, will be considered reasonable in the context of effective pain relief, as long as patients or consumers are informed. Even as the risks get more significant, substantial pain relief will be considered a large enough benefit to out-weigh a range of negative side effects in many cases.
So far, so straightforward. Continue reading
The primary season is now well underway, and the Trump bandwagon continues to gather pace. Like most observers, I thought it would run out of steam well before this stage. Trump delights in the kinds of vicious attacks and stupidities that would derail any other candidate. His lack of shame and indifference to truth give him a kind of imperviousness to criticism. His candidacy no longer seems funny: it now arouses more horror than humor for many observers. Given that Trump is so awful – so bereft of genuine ideas, of intelligence, and obviously of decency – what explains his poll numbers? Continue reading
Department of Psychology
CITY UNIVERSITY LONDON
A runaway trolley is approaching a fork in the tracks. If the trolley is allowed to run on its current track, a work crew of five will be killed. If the driver steers the train down the other branch, a lone worker will be killed. If you were driving this trolley what would you do? What would a computer or robot driving this trolley do? Autonomous systems are coming whether people like it or not. Will they be ethical? Will they be good? And what do we mean by “good”?
Many agree that artificial moral agents are necessary and inevitable. Others say that the idea of artificial moral agents intensifies their distress with cutting edge technology. There is something paradoxical in the idea that one could relieve the anxiety created by sophisticated technology with even more sophisticated technology. A tension exists between the fascination with technology and the anxiety it provokes. This anxiety could be explained by (1) all the usual futurist fears about technology on a trajectory beyond human control and (2) worries about what this technology might reveal about human beings themselves. The question is not what will technology be like in the future, but rather, what will we be like, what are we becoming as we forge increasingly intimate relationships with our machines. What will be the human consequences of attempting to mechanize moral decision-making?
Every day, for about thirty-five minutes, I sit cross-legged on a cushion with my eyes shut. I regulate my breath, titrating its speed against numbers in my head; I watch my breath surging and trickling in and out of my chest; I feel the air at the point of entry and exit; I export my mind to a point just beyond my nose and pour the breath into that point. When my mind wanders off, I tug it back.
The practice is systematic and arduous. In some ways it is complex: it involves 16 distinct stages. When I am tired, and the errant mind won’t come quietly back on track, I find it helpful to summarise the injunctions to myself as:
- I am here
- This is it
I alternate the emphases: ‘I am here’: ‘I am here’; ‘I am here’; ‘This is it’; ‘This is it’; ‘This is it.’
I note (although not usually, and not ideally, when I’m in the middle of the practice) that each of these connotations presumes something about the existence of an ‘I’. This is less obvious with the second proposition, but clearly there: ‘This’ is something that requires a subject. Continue reading
Written by Anke Snoek
I have a 3 year old who doesn’t eat. He seems not to be interested in food in general. We were offered many explanations for why he doesn’t eat and most specialists suspect a psychological source for his lack of appetite. But recently a friend suggested that maybe there is something wrong with the muscles in his mouth that makes it hard to swallow. I wondered: why didn’t I get offered more of these physical explanations as opposed to psychological ones? What makes ‘not eating’ almost by definition a mental disorder for most people? What other behaviour are we inclined to label as a mental disorder rather than staying open for other explanations? Continue reading
One of the most stunning successes I have personally seen in my life is the emergence of the Effective Altruism movement. I remember when Will Crouch (now MacAskill) first presented 80 000 hours to our Graduate Discussion Group and Toby Ord was still a grad student. From their ideas a whole movement has emerged of brilliant young people galvanised into doing good. We are getting the brightest, best people of the current generation coming to Oxford to engage with the Centre for Effective Altruism. Almost every grad student I come across has some connection. Well done Will and Toby, and all those others who have contributed to establishing this movement
So I guess I should not have been surprised when during my visit to Harvard this week, a student contacted me from EA to give an ad hoc talk. I discovered there were cells all over the world and the movement had spread way beyond Oxford.
Anyway, I gave an impromptu talk and predictably there were many questions I could not answer satisfactorily. One the issues I covered was the need to create a new basic (or minimal) secular morality. This is necessary not only to decide what the goals of moral bioenhancement should be (my favourite current pet topic), but indeed how education should be revised and society ordered. Every society has a set of normative commitments. Ours are outdated, archaic and unfit for the challenges of a globalised, interconnected and technologically advanced world.
Guest Post: Pervitin instead of coffee? Change in attitudes to cognitive enhancement in the 50’s and 60’s in Brazil
Written by Marcelo de Araujo
State University of Rio de Janeiro
CNPq – The Brazilian National Council for Scientific and Technological Development
How does our attitude to drugs in general shape our reaction to “smart drugs” in particular? Ruairidh Battleday and Anna-Katharine Brem have recently published a systematic review of 24 studies on the effect of modafinil on healthy individuals. They concluded that “modafinil may well deserve the title of the first well-validated pharmaceutical ‘nootropic’ agent.” This publication has rekindled the debate on the ethics of “smart drugs”. Of course further studies are necessary for a better assessment of the safety and efficacy of modafinil. But if modafinil, or some other drug, proves safe and effective in the future, are there reasons to oppose its widespread use in society?